PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

LIPIODOL® ULTRA FLUID

Ethiodized Oil Injection, House Std
Solution for injection, 38% w/w (380 mg iodine/g or 480 mg iodine/mL)

V08AE non-watersoluble X-ray contrast media

For professional use only

Guerbet
BP 57400
95943 Roissy CdG Cedex
France

Date of Preparation: July 12, 2017
Submission Control No: 196107
# Table of Contents

## PART I: HEALTH PROFESSIONAL INFORMATION

- SUMMARY PRODUCT INFORMATION ................................................................. 3  
- INDICATIONS AND CLINICAL USE .................................................................. 3  
- CONTRAINDICATIONS ...................................................................................... 4  
- WARNINGS AND PRECAUTIONS ...................................................................... 4  
- ADVERSE REACTIONS ...................................................................................... 7  
- DRUG INTERACTIONS ....................................................................................... 9  
- DOSAGE AND ADMINISTRATION ..................................................................... 10  
- OVERDOSAGE ................................................................................................. 12  
- ACTION AND CLINICAL PHARMACOLOGY ..................................................... 12  
- STORAGE AND STABILITY ............................................................................. 12  
- DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................... 12

## PART II: SCIENTIFIC INFORMATION

- PHARMACEUTICAL INFORMATION ................................................................. 14  
- CLINICAL TRIALS .......................................................................................... 14  
- REFERENCES .................................................................................................... 18

## PART III: PATIENT MEDICATION INFORMATION

................................................................. 19
LIPIODOL® ULTRA FLUID
Ethiodized Oil Injection, House Std

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intralymphatic, Intracavitary, Selective intra-arterial</td>
<td>Solution for injection, 380 mg iodine/g (38% w/w), 480 mg iodine/mL</td>
<td>None</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

LIPIODOL ULTRA FLUID (ethiodized oil) is an X-ray contrast media indicated for:

Adult patients:
- Lymphography
- Hysterosalpingography
- Sialography
- Fistulography
- Selective hepatic intra-arterial use for imaging tumors in patients with known hepatocellular carcinoma (HCC)

Pediatric patients (< 18 years of age):
- Lymphography

LIPIODOL ULTRA FLUID should be administered by health professional experienced in the respective imaging procedure in a controlled clinical setting where adequate facilities and expertise for the management of serious adverse events are readily available.

Geriatrics (> 65 years of age):
Evidence from clinical experience suggests that use in elderly patients with diseases of the cardiovascular, respiratory or nervous systems is associated with an increased risk of serious adverse reactions (see WARNINGS AND PRECAUTIONS). LIPIODOL ULTRA FLUID must be administered with caution in these patients, based on individual benefit-risk evaluation.
CONTRAINDICATIONS

- Hypersensitivity reaction to ethiodized oil or iodine
- Manifest hyperthyroidism
- Traumatic injuries, recent hemorrhage or bleeding (risk of extravasation or embolism)
- Bronchography
- Intravenous, intra-arterial (apart from authorized selective use) or intrathecal administration
- LIPIODOL ULTRA FLUID hysterosalpingography is also contraindicated in pregnancy, acute pelvic inflammatory disease, marked cervical erosion, endocervicitis and intrauterine bleeding, in the immediate pre-or postmenstrual phase, or within 30 days of curettage or conization.
- LIPIODOL ULTRA FLUID lymphography is also contraindicated in patients with a right to left cardiac shunt, advanced pulmonary disease, tissue trauma or hemorrhage advanced neoplastic disease with expected lymphatic obstruction, previous surgery interrupting the lymphatic system, or radiation therapy to the examined area.
- Sialography with LIPIODOL ULTRA FLUID is also contraindicated in case of acute parotiditis.
- LIPIODOL ULTRA FLUID selective hepatic intra-arterial use is also contraindicated in areas of the liver where the bile ducts are dilated (unless external biliary drainage was performed before injection), in case of advanced liver failure (Child-Pugh Class C), macroscopic vascular invasion of the main portal vein (right, left or common trunk) or hepatic vein or vena cava, and/or extensive extra-hepatic metastasis of the tumor.

WARNINGS AND PRECAUTIONS

<table>
<thead>
<tr>
<th>Serious Warnings and Precautions</th>
</tr>
</thead>
</table>

LIPIODOL ULTRA FLUID should be administered by health professional experienced in the respective imaging procedure in a controlled clinical setting where adequate facilities and expertise for the management of serious adverse events are readily available. LIPIODOL ULTRA FLUID should be administered slowly with radiologic monitoring without exceeding the recommended dose.

Serious or fatal pulmonary or cerebral embolism has been reported following intralymphatic and selective intra-arterial use, and after inadvertent systemic intravascular injection or intravasation (See WARNING AND PRECAUTION).

Serious or fatal cases of exacerbation of chronic liver disease and related conditions have been reported after the selective intra–arterial administration of LIPIODOL ULTRA FLUID (See WARNING AND PRECAUTION).
Cardiovascular

**Embolization of the lung, brain and other major organs**

Pulmonary embolism may occur immediately or a few hours to days following lymphography, intra-arterial use, or inadvertent systemic vascular injection or intravasation of LIPIODOL ULTRA FLUID, causing decreased pulmonary diffusing capacity and pulmonary blood flow, pulmonary infarction, acute respiratory distress syndrome, or fatalities.

Embolization of the brain and less commonly other major organs has also been reported.

LIPIODOL ULTRA FLUID is not recommended in patients with impaired lung function, cardiorespiratory failure, or pre-existing right-sided cardiac overload, in particular elderly patients. Radiological monitoring should be performed during the LIPIODOL ULTRA FLUID injection. Do not exceed the recommended maximum dose and rate of injection of LIPIODOL ULTRA FLUID.

During lymphography to minimize the risk of pulmonary embolism, obtain radiographic confirmation of intralymphatic (rather than venous) injection, and terminate the procedure when LIPIODOL ULTRA FLUID becomes visible in the thoracic duct or lymphatic obstruction is observed.

Endocrine and Metabolism

**Thyroid dysfunction**

Iodinated contrast media can affect thyroid function because of the free iodine content and can cause hyperthyroidism or hypothyroidism in predisposed patients. Patients at risk are those with latent hyperthyroidism and those with Hashimoto thyroiditis, or history of thyroid irradiation. Iodism occurs more frequently with LIPIODOL ULTRA FLUID than with water-soluble organic iodine derivatives. Iodism (iodine toxicity or poisoning) is a syndrome caused by iodine or any iodine compound and manifested by loss of appetite, sickness, tachycardia, headache, abdominal pain, intestinal transit disorder, extreme tiredness, taste disturbance, corysa, skin irritation, depression, parotid gland swelling.

As LIPIODOL ULTRA FLUID may remain in the body for several months, thyroid diagnostic results can be affected for up to two years.

In patients at risk, the thyroid function must be assessed before LIPIODOL ULTRA FLUID administration. LIPIODOL ULTRA FLUID is contraindicated in manifest hyperthyroidism (see CONTRAINDICATIONS).

Hepatic/Biliary/Pancreatic

**Exacerbation of chronic liver disease**

LIPIODOL ULTRA FLUID selective hepatic intra-arterial administration can exacerbate the following conditions: portal hypertension causing variceal bleeds due to obstruction of intrahepatic portal channels by opening a pre-sinusoidal anastomosis, hepatic ischemia with liver enzyme elevations, fever and abdominal pain, hepatic failure resulting in ascites and encephalopathy. Hepatic vein thrombosis, irreversible liver insufficiency and fatalities have been...
reported. Procedural risks include vascular complications and infections.

LIPIODOL ULTRA FLUID use is contraindicated in areas of the liver where the bile ducts are dilated (unless external biliary drainage was performed before injection), advanced liver failure (Child-Pugh Class C), macroscopic vascular invasion of the main portal vein (right, left or common trunk or hepatic vein or vena cava), and/or extensive extra-hepatic metastasis of the tumor (see CONTRAINDICATIONS). Patients with esophageal varices should be carefully monitored for rupture during the procedure.

Immune

**Hypersensitivity**

Anaphylactic and anaphylactoid reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following LIPIODOL ULTRA FLUID administration, independent of the dose. Most hypersensitivity reactions to LIPIODOL ULTRA FLUID occur within half an hour after administration.

Avoid use in patients with a history of sensitivity to other iodinated contrast agents (see CONTRAINDICATIONS), bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL ULTRA FLUID. Administer LIPIODOL ULTRA FLUID only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation; ensure continuous medical monitoring and maintain an intravenous access line. Delayed reactions can occur up to several days after administration. Observe patients for signs and symptoms of hypersensitivity reactions during and for at least 30 minutes following LIPIODOL ULTRA FLUID administration, and warn patients of the possibility of delayed reactions.

Renal

Iodinated contrast agents can induce a transient deterioration of renal function or exacerbation of persisting renal insufficiency. Acute renal failure, including fatal cases has been reported in patients following selective intra-arterial use of LIPIODOL ULTRA FLUID. Patients at risk of contrast media-induced nephrotoxicity include those with pre-existing renal impairment, diabetes mellitus, sepsis, hypotension, dehydration, cardiovascular disease, older age, multiple myeloma, hypertension, and hyperuricemia, children under one year of age and elderly patients with atheroma and co-administered nephrotoxic medications (see DRUG INTERACTIONS).

Prior to the intra-arterial administration, all patients should be screened for renal dysfunction by obtaining history and/or laboratory tests. Preventative measures in patients at risk include adequate hydration, avoidance of nephrotoxic medications, and temporary interruption of metformin to manage the risk of lactic acidosis triggered by dehydration in diabetic patients (see DRUG INTERACTIONS). Consider follow-up renal function assessments for patients with a history of renal dysfunction.

Respiratory
LIPIODOL ULTRA FLUID administration may aggravate symptoms of an existing asthma.

In patients with uncontrolled asthma, LIPIODOL ULTRA FLUID should be used with caution, based on individual benefit-risk evaluation.

Special Populations

Pregnant Women: There are no adequate and well-controlled studies of LIPIODOL ULTRA FLUID in pregnant women.

LIPIODOL ULTRA FLUID hysterosalpingography is contraindicated in pregnancy (see CONTRAINDICATIONS). Limited clinical data is available for LIPIODOL ULTRA FLUID during pregnancy for other procedures; however, administration of LIPIODOL ULTRA FLUID causes iodine transfer which may interfere with the thyroid function of the fetus and result in brain damage and permanent hypothyroidism. LIPIODOL ULTRA FLUID must only be used in pregnancy if absolutely necessary.

Cumulatively to date (2017), twenty-two cases of drug exposure during pregnancy based on spontaneous reporting have been reported. In the vast majority of the overall 22 case reports (77%), the mother received Lipiodol for hysterosalpingography for infertility before getting pregnant (n=16) or accidentally at the very beginning of an unknown pregnancy (n=1). Among the 17 reports fetal drug exposure were reported in mothers received LIPIODOL ULTRA FLUID for hysterosalpingography, there were six case reports of fetal goiter, three cases of hypothyroidism in the neonate and one report each of missed abortion, abortion and premature delivery.

Neonates exposed to LIPIODOL ULTRA FLUID in utero should be tested for thyroid function and receive careful medical monitoring.

Nursing Women: LIPIODOL ULTRA FLUID is excreted in human milk. Iodine has been shown to pass into the vascular bed via the digestive tract of infants and could interfere with the thyroid function.

LIPIODOL ULTRA FLUID use should be avoided in a nursing woman because of risk of hypothyroidism in nursing infants. If breastfeeding is continued, the neonate’s thyroid function should be monitored.

Geriatrics (> 65 years of age): There are no studies conducted in geriatric patients. Evidence from clinical experience suggests that use in elderly patients with cardiovascular, respiratory or nervous systems is associated with an increased risk of serious adverse reactions. LIPIODOL ULTRA FLUID must be administered with caution in these patients, based on individual benefit-risk evaluation.

ADVERSE REACTIONS
Post-Market Adverse Drug Reactions
The following adverse reactions have been identified in the literature and based on spontaneous reporting in the post-market setting and are presented by MedDRA preferred term. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Table 1: Post-Market Adverse Reactions experience

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Adverse reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrine disorders</td>
<td>hypothyroidism, hyperthyroidism, thyroiditis</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>retinal vein thrombosis</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>nausea, vomiting, diarrhoea</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>fever, pain, granuloma</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>hepatic vein thrombosis</td>
</tr>
<tr>
<td>Immune disorders</td>
<td>hypersensitivity, anaphylactic reaction, anaphylactoid reaction</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>cerebral embolism</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>pulmonary embolism, dyspnea, cough, acute respiratory distress syndrome</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Renal failure</td>
</tr>
<tr>
<td>Vascular system disorders</td>
<td>lymphoedema aggravation</td>
</tr>
</tbody>
</table>

Serious adverse reactions are described in more detail in WARNINGS AND PRECAUTIONS section:

Adverse reactions specific to the condition of use are as follows:

**Sialography**
A secondary inflammation reaction can sometimes occur with functional glandular paralysis (salivary duct inflammation) which disappears within 48 hours.

**Hysterosalpingography**
Abdominal pain, foreign body reactions, exacerbation of pelvic inflammatory disease.

**Lymphography**
Cardiovascular collapse, lymphangitis, thrombophlebitis, edema or exacerbation of pre-existing lymphedema, dyspnea and cough, fever, iodism (headache, soreness of mouth and pharynx, coryza and skin rash), allergic dermatitis, lipogranuloma, delayed healing at the site of incision.

**Selective Hepatic Intra-arterial Injection**
Fever, abdominal pain, nausea, vomiting and diarrhea are the most common reactions; other reactions include blood glucose abnormalities, blood pressure increased, cholecystitis, carcinoid crisis, hepatic ischemia, liver enzymes abnormalities, transitory decrease in liver function, liver decompensation or failure, hepatic encephalopathy, biloma, hepatic abscess, bacteraemia, sepsis, renal insufficiency or failure, gastrointestinal bleeding due to ruptured varices or ulcer. Procedural risks include vascular complications, ascites and access site injuries and infections.

**DRUG INTERACTIONS**

**Drug-Drug Interactions**

**Beta blockers**
Patients on beta blockers including ophthalmic beta blockers may be at risk of treatment-refractory anaphylaxis due to reduced response to adrenaline.

Other vasoactive substances that may potentially reduce the effectiveness of the sympathomimetic drugs and the beta-adrenergic effects of adrenaline include angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers.

It is important to be familiar with the practice of emergency measures so that prompt action may be taken in the event of hypersensitivity reactions. To permit immediate countermeasures to be taken in emergencies, appropriate drugs and instruments, e.g., endotracheal tube and ventilator, should be readily available.

**Interleukin II**
Interleukins are associated with an increased prevalence of delayed hypersensitivity/anaphylactoid reactions after iodinated contrast agent administration. These reactions include flu-like symptoms, fever, chills, nausea, vomiting, pruritus, rash, diarrhea, hypotension, edema, oliguria, and joint pain.

**Metformin**
Lactic acidosis triggered by impaired renal function may be induced by intra-arterial administration of LIPIODOL ULTRA FLUID in diabetic patients. For patients scheduled to undergo examination, treatment with metformin must be suspended 48 hours before the investigation and only restarted 2 days after the radiological examination.

**Diuretics**
In the event of dehydration provoked by diuretics, the risk of acute renal failure is increased, especially when high doses of iodinated contrast agents are used.
Patients should be receive re-hydration before intra-arterial administration of LIPIODOL ULTRA FLUID

**Nephrotoxic medications**
Iodinated contrast agents can induce a transient deterioration of renal function or exacerbation of persisting renal insufficiency. Avoid combinations with nephrotoxic medicines (e.g., aminoglycosides, organoplatinum compounds, high doses of methotrexate, pentamidine, foscarnet and certain antiviral agents [e.g., aciclovir, ganciclovir, valaciclovir, adefovir, cidofovir, tenofovir], vancomycin, amphotericin B, immunosuppressants such as cyclosporine or tacrolimus).

If such a combination is necessary, laboratory monitoring of renal function must be intensified

**Drug-Laboratory Interactions**
Following LIPIODOL ULTRA FLUID administration, the product remains in the body for several months, and may interfere with thyroid function testing for up to two years. LIPIODOL ULTRA FLUID interferes with radioactive iodine uptake by thyroid tissue for several weeks to months and may impair visualization of thyroid scintigraphy and reduce effectiveness of iodine 131 treatment.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**
LIPIODOL ULTRA FLUID is for intralymphatic, intracavitary and selective intra-arterial use.

**Recommended Dose, Dosage Adjustment and Administration**
Inspect LIPIODOL ULTRA FLUID visually for particulate matter and discoloration before administration. Do not use the solution if particulate matter is present or if the container appears damaged. LIPIODOL ULTRA FLUID is a clear, pale yellow to amber colored oil; do not use if the color has darkened.

Draw LIPIODOL-ULTRA FLUID into a glass syringe and use promptly. Use the smallest possible amount of LIPIODOL ULTRA FLUID according to the anatomical area to be visualized. Discard any unused portion of LIPIODOL ULTRA FLUID.

**Hysterosalpingography**
Using aseptic technique, inject LIPIODOL ULTRA FLUID into the endometrial cavity with fluoroscopic control. Inject increments of 2 mL of LIPIODOL ULTRA FLUID until tubal patency is determined; stop the injection if patient develops excessive discomfort. Re-image after 24 hours to establish whether LIPIODOL ULTRA FLUID has entered the peritoneal cavity. The examination should be carried out on the 10th day following the start of the menstrual period and must be carried out no later than the 12th day.
**Lymphography**
Inject LIPIODOL ULTRA FLUID into a lymphatic vessel under radiologic guidance to prevent inadvertent venous administration or intravasation.

**Adults:**
- unilateral lymphography of the upper extremities 2 to 4 mL
- unilateral lymphography of the lower extremities 6 to 8 mL
- penile lymphography 2 to 3 mL
- cervical lymphography 1 to 2 mL

After chemotherapy or radiotherapy, the lymph nodes shrink significantly and retain only a small amount of the contrast agent. Doses must then be reduced.

**Pediatric Patients:**
Use a dose of minimum of 1 mL to a maximum of 6 mL according to the anatomical area to be visualized. Do not exceed 0.25 mL/kg. The dose should be proportionally decreased in children: in infants between 1 and 2 years of age, a dose of 1 mL per extremity is sufficient.

The following method is recommended for lymphography of the upper or lower extremities. Start the injection of LIPIODOL ULTRA-FLUID into a lymphatic channel at a rate not to exceed 0.2 mL per minute. Inject the total dose of LIPIODOL ULTRA FLUID in no less than 1.25 hours. Use frequent radiologic monitoring to determine the appropriate injection rate and to follow the progress of LIPIODOL ULTRA FLUID within the lymphatics. Interrupt the injection if the patient experiences pain. Terminate the injection if lymphatic blockage is present to minimize introduction of LIPIODOL ULTRA FLUID into the venous circulation via lymphovenous channels. Terminate the injection as soon as LIPIODOL ULTRA FLUID is radiographically evident in the thoracic duct to minimize entry of LIPIODOL ULTRA FLUID into the subclavian vein and pulmonary embolization. A radiographic or fluoroscopic control during injection allows to avoid overdosing. Obtain immediate post-injection images. Re-image at 24 or 48 hours to evaluate nodal architecture.

**Sialography**
Inject LIPIODOL ULTRA FLUID until the gland fills. Do not exceed 5 mL.

**Fistulography**
Inject LIPIODOL ULTRA FLUID until fistulae fills. Do not exceed 5 mL.

**Selective Hepatic Intra-arterial Use**
The dose depends on the tumor size, and local blood flow in the liver and in the tumor.

Administration is by selective intra-arterial catheterization of the hepatic artery. Inject from 1.5 to 15 mL slowly under continuous radiologic monitoring. Stop the injection when stagnation or reflux is evident. Limit the dose to only the quantity required for adequate visualization. The total dose of LIPIODOL ULTRA FLUID administered should not exceed 15 mL.
OVERDOSAGE

Overdose may lead to respiratory, cardiac or cerebral complications, which can potentially be fatal. Microembolisms may occur more frequently in the context of overdose.

Promptly initiate symptomatic treatment and support of all vital functions for overdose.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action
LIPIODOL ULTRA FLUID is a radio-opaque, iodinated poppy seed oil-based contrast agent.

Pharmacokinetics
Following an injection administered through lymphatic vessels, LIPIODOL ULTRA FLUID is transported by the blood to the liver and lungs where the lipid droplets are broken down in the pulmonary alveoli, the spleen and adipose tissues. LIPIODOL ULTRA FLUID can be retained for several weeks or months following lymphography.

When given into the hepatic artery, LIPIODOL ULTRA FLUID has been found to remain selectively in the neovasculature and extravascular tissues of the HCC for several weeks to over a year, while it is cleared from normal liver parenchyma within a few days (7 days is commonly cited).

LIPIODOL ULTRA FLUID releases iodine which is eliminated by the urine in the form of iodide.

STORAGE AND STABILITY

LIPIODOL ULTRA FLUID should be protected from light. Store at room temperature up to 30°C.

DOSAGE FORMS, COMPOSITION AND PACKAGING

LIPIODOL ULTRA FLUID is available in self-breaking ampoules of 10 mL
LIPIODOL ULTRA FLUID is a water insoluble iodinated contrast media. (i.e., ethyl esters of iodized fatty acids of poppy seed oil).
One gram of LIPIODOL ULTRA FLUID contains 0.38 g of iodine.
One milliliter of LIPIODOL ULTRA FLUID contains 0.48 g of iodine.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Common name: Ethyl esters of iodized fatty acids of poppy-seed oil

Chemical name: Ethyl esters of iodized fatty acids of poppy-seed oil (EEIFA).
Ethiodized oil injection is an iodine addition product of the ethyl ester of the fatty acids of poppyseed oil.

Molecular formula: Not applicable

Molecular mass: Not applicable

Structural formula: The drug substance is a mixture of ethyl esters of iodized and non-iodized fatty acids. The indicative proportions of the main compounds of this mixture are given in the table below.

<table>
<thead>
<tr>
<th>Name</th>
<th>Abbreviation</th>
<th>Molecular formula</th>
<th>Mw (g/mol)</th>
<th>%w/w</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethyl palmitate</td>
<td>Ethyl C16:0</td>
<td>C_{18}H_{36}O_2</td>
<td>284</td>
<td>4.6 to 6.7</td>
</tr>
<tr>
<td>Ethyl stearate</td>
<td>Ethyl C18:0</td>
<td>C_{20}H_{40}O_2</td>
<td>312</td>
<td>0.8 to 1.9</td>
</tr>
<tr>
<td>Ethyl monoiodostearate</td>
<td>Ethyl C18:1:0</td>
<td>C_{20}H_{39}I_{2}O_2</td>
<td>438</td>
<td>11.3 to 15.3</td>
</tr>
<tr>
<td>Ethyl diiodostearate</td>
<td>Ethyl C18:12:0</td>
<td>C_{20}H_{38}I_{2}O_2</td>
<td>564</td>
<td>73.5 to 82.8</td>
</tr>
</tbody>
</table>

Physicochemical properties: EEIFA is a pale yellow oily liquid.
Its density at 20° C is 1.280.
EEIFA is practically insoluble in water.
One gram of EEIFA contains 0.38 g of iodine.
One milliliter of EEIFA contains 0.48 g of iodine.

CLINICAL TRIALS

Clinical efficacy evidence supporting LIPIODOL ULTRA FLUID for selective intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC) is based on published literatures. Two studies were identified as pivotal, based on sensitivity and specificity results.
compared with other imaging modalities.

**Lipiodol Computerized Tomography: How Sensitive and Specific is the Technique in the Diagnosis of Hepatocellular Carcinoma? (Ngan H, 1990)**

This study was performed to analyze the pattern of uptake of Lipiodol in the liver on computed tomography (CT), to study the sensitivity and specificity of Lipiodol-CT (compared with angiography) and to evaluate if Lipiodol-CT can detect an HCC while it is still small and therefore improve resectability rate.

This was a single center, prospective, single arm study. Lipiodol-CT was performed in 60 patients with either persistently raised serum AFP levels above 20 ng/mL or abnormalities in ultrasound (US) of the liver. Data was collected over a 4 year period. The series included 53 men and 7 women with ages ranging from 16 to 78 years. Most of these patients were hepatitis-B surface antigen positive and were closely followed up at 3-6 monthly intervals because of chronic active hepatitis, cirrhosis or a history of hepatic resection for HCC. A conventional hepatic angiogram was performed prior to Lipiodol-CT. Then 2-5 mL of Lipiodol was selectively infused into the common hepatic artery or into the celiac axis if selective catheterization of the common hepatic artery was not possible. CT of the upper abdomen was performed 6-13 days after the injection of Lipiodol. Information about image evaluation (blinded/unblinded; one reader/consensus reads) is not available. The true standard for diagnosis of HCC is composited of persisted high AFP, ultrasound and/or histology confirmation after hepatic resection.

HCC was present in 34 out of 60 patients. Lipiodol-CT had an overall sensitivity of 97.1%, an accuracy of 88.3% and a specificity of 76.9% in the diagnosis of HCC. A total of 33 HCCs were correctly diagnosed by Lipiodol-CT (true positive). There were, however, 6 false positives: 2 lesions turned out to be focal nodular hyperplasia, 2 hemangioma, 1 was a metastasis and 1 was a regenerative nodule. HCC was correctly excluded in 20 patients. Conventional hepatic angiography detected the HCCs with certainty in 25 patients (sensitivity, 73.6%). US was performed on 21 patients with HCCs and detected the tumors in only 10 patients (sensitivity, 47.6%).

**Table 3: Summary of results of sensitivity and specificity**

<table>
<thead>
<tr>
<th>Imaging Modality</th>
<th>True Positive (+)</th>
<th>True Positive</th>
<th>Sensitivity Estimate</th>
<th>True Negative (+)</th>
<th>True Negative</th>
<th>Specificity Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipiodol-CT</td>
<td>34</td>
<td>33</td>
<td>97.06</td>
<td>26</td>
<td>20</td>
<td>76.92</td>
</tr>
<tr>
<td>US</td>
<td>21</td>
<td>10</td>
<td>47.62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiography</td>
<td>34</td>
<td>25</td>
<td>73.53</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MRI of Small Hepatocellular Carcinoma: Comparison with US, CT, DSA, and Lipiodol-CT (De Santis M et al., 1992)

This study was conducted to compare the diagnostic value of magnetic resonance imaging (MRI) with that of US, pre- and post-contrast CT, digital subtraction angiography (DSA) and CT after injection of Lipiodol (Lipiodol-CT) in the diagnosis of small HCC (< 3 cm).

This was a single center, intra-individual comparative study. A total of 30 cirrhotic patients who developed HCC were examined and 13 patients (10 men and 3 women, 52-69 years old) who demonstrated the presence of at least one HCC nodule < 3 cm in size, were included in study. HCC was diagnosed by percutaneous tissue-core biopsy under US in 11 patients and by combined findings of various imaging techniques in the remaining two patients.

Real-time sonography was performed using a convex scanner (3.5 MHZ). MR was performed using 1.5 T system. Pre- and post-contrast CT were performed in 12 of 13 patients with Iopamiron (200-250 mL) administered intravenously for contrast-enhanced CT. DSA was performed and the contrast material (30 mL) for DSA was injected at the rate of 4-5 mL/s. Following angiography, 4-8 mL of Lipiodol was injected in the common hepatic artery (7 patients) and proper hepatic artery (6 patients). Lipiodol-CT was performed 1-2 weeks after DSA in all patients, except one patient who was examined on the same day as DSA and 23 days later. A repeat Lipiodol-CT was performed in 4 patients 1-3 months after DSA and 2 of them were re-examined 6 months later. One patient was re-examined one month after DSA.

All the techniques employed (US, MR, CT, DSA, and Lipiodol-CT) enabled 27 small HCCs to be detected in the 13 patients. The detection rate (sensitivity) for HCC nodules was 63% by MR, 67% by US, 50% by CT, 74% by DSA and 93% by Lipiodol-CT.

<table>
<thead>
<tr>
<th></th>
<th>Number of Patients</th>
<th>Number of Tumors Detected</th>
<th>Total Tumors Examined</th>
<th>Sensitivity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipiodol-CT</td>
<td>13</td>
<td>25</td>
<td>27</td>
<td>92.59</td>
</tr>
<tr>
<td>CT</td>
<td>12</td>
<td>12</td>
<td>24</td>
<td>50.00</td>
</tr>
<tr>
<td>MR</td>
<td>13</td>
<td>17</td>
<td>27</td>
<td>62.96</td>
</tr>
<tr>
<td>US</td>
<td>13</td>
<td>18</td>
<td>27</td>
<td>66.67</td>
</tr>
<tr>
<td>DSA</td>
<td>13</td>
<td>20</td>
<td>27</td>
<td>74.07</td>
</tr>
</tbody>
</table>

**TOXICOLOGY**

Genotoxicity
A battery of in vitro and in vivo genotoxicity tests performed with Lipiodol proved to be
negative:
- In vitro bacterial reverse mutation test performed on Salmonella Typhimurium strains TA1535, TA1537, TA98, TA102, and TA100 at tested concentrations up to 240 mg/plate, by both pre-incubation and plate-incorporation methods with or without metabolic activation,
- In vitro cytogenetic evaluation of chromosomal damages (L5178Y mouse lymphoma cells TK+/-), conducted at concentrations up to 5000 µg/mL with or without metabolic activation
- In vivo chromosomal damage assay in bone marrow of rats (micronucleus test) by the intravenous route at 48, 240, and 479 mg/kg.

LIPIODOL ULTRA FLUID can be thus considered to be devoid of genotoxic potential.

Carcinogenicity
No study available.

Reproduction and developmental toxicity
There is no available data on potential effects of Lipiodol on fertility and reproductive performance.

Embryo-fetotoxic potential and teratogenic effects of LIPIODOL ULTRA FLUID have been evaluated in rats and rabbits after oral administration:
- Female rats were dosed daily with Lipiodol from gestation days 6 to 17 at doses of 50, 110, and 250 mg iodine/kg/day. The fetuses were removed on gestation day 20 by cesarean section.
- Female rabbits were dosed daily with Lipiodol from gestation days 6 to 18 at doses of 12.5, 25, and 50 mg iodine/kg/day (study 1), and every 3 days from gestation days 6 to 18 at a dose of 12.5 mg iodine/kg/day (study 2). The fetuses were removed on gestation day 29 by cesarean section.

In both species, mortality, clinical signs, food consumption, gestation body weight were regularly noted until the foetuses were removed by cesarean section. Gestation parameters were recorded (number of implantation, corporea lutea, pre/post implantation losses, fetal weight, sex ratio). An external examination of maternal organs and foetuses was conducted. Foetuses were examined for visceral and skeletal abnormalities

LIPIODOL ULTRA FLUID is neither embryofoetotoxic nor teratogenic in rats and rabbits after oral administration.
REFERENCES


READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION

LIPIODOL ULTRA FLUID
Ethiodized Oil Injection, House Std

Read this carefully before you start taking LIPIODOL ULTRA FLUID. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about LIPIODOL ULTRA FLUID.

### Serious Warnings and Precautions

LIPIODOL ULTRA FLUID is given by a doctor who knows how to treat life threatening reactions. Your doctor will watch your health before, during and after the exam. They know what safety measures to take. They are aware of the possible complications. They are experienced in doing X-ray tests. This drug is only used at sites with drugs, equipment and staff that can handle serious emergencies. They will monitor you for at least 30 minutes after the drug is given. Each patient must have an intravenous line open for use. LIPIODOL ULTRA FLUID should be given slowly with X-ray monitoring. The doctor should not exceed the recommended dose.

Serious or fatal events can occur when LIPIODOL ULTRA FLUID is used. They include:

- Blockage of certain blood vessels in the brain (cerebral embolism) or in the lung (pulmonary embolism)
- **Worsening chronic liver disease** which may last over a period of six months.

---

**What is LIPIODOL ULTRA FLUID used for?**

It is a drug used in X-ray tests.

LIPIODOL ULTRA FLUID is indicated for:

- Lymphography: to see lymphatic vessels and lymph nodes in adults and children.
- Hysterosalpingography: to see the uterus and fallopian tubes in adult women.
- Sialography: to see the salivary glands in adults.
- Fistulography: to see fistulas, a kind of abnormal channel in the body, in adults.
- Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC): to see tumors in the liver, in adults.

**How does LIPIODOL ULTRA FLUID work?**

LIPIODOL ULTRA FLUID helps tissues to appear darker or brighter depending on the test. This makes it easier for the doctor to detect any abnormalities.

Your doctor performs the test immediately after using LIPIODOL ULTRA FLUID. Your doctor may need to repeat the test after 24-48 hours.

**What are the ingredients in LIPIODOL ULTRA FLUID?**

Medicinal ingredients: ethyl esters of iodized fatty acids of poppy-seed oil.

Non-medicinal ingredients: none

**LIPIODOL ULTRA FLUID comes in the following dosage forms:**

- a solution for injection,
- supplied as 380 mg iodine/g (38% w/w), corresponding to 480 mg iodine/mL,
- packaged in a self-breaking 10 mL ampoule.
Do not use LIPIODOL ULTRA FLUID if:

- you ever had an allergic reaction to LIPIODOL ULTRA FLUID or to any other iodine product. This can also be called Allergic Disorders,
- you have hyperthyroidism,
- you have traumatic injuries or recent bleeding,
- you have acute parotiditis (swelling of the salivary gland) and are imaging salivary glands,
- you are undergoing bronchography. This is a type of X-ray exam of the lung,
- you are pregnant or have disease, infection, bleeding or recent surgical procedures of the genital organs. This applies if you need to have an exam of the uterus and fallopian tubes,
- you suffer from heart or lung disease; you have a tumor, recent surgery or radiation therapy that blocks lymph nodes. This applies if you will receive lymphography.
- you have a liver disease and you have blocked bile ducts, unless a drainage tube is in place before the test; you have advanced liver failure or cancer in veins of the liver; or you have cancer spread from the liver. These apply if you will receive LIPIODOL ULTRA FLUID in your liver.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take LIPIODOL ULTRA FLUID. Talk about any health conditions or problems you may have, including if:

- you suffer or have suffered from an allergy (eg, hay fever, hives) or asthma,
- you suffer from lung or cardiac diseases,
- you have an over-active thyroid,
- you have diabetes,
- you have uterine bleeding and infection,
- you have pelvic inflammation,
- you are pregnant or planning to get pregnant. LIPIODOL ULTRA-FLUID can result in brain damage and permanent hypothyroidism in the baby.
- you are breastfeeding. LIPIODOL ULTRA-FLUID can pass through breast milk. It can result in hypothyroidism in the baby,
- you are in the few days before or immediately after your monthly period,
- you have a disease of the kidney,
- you suffer from an accumulation of fluid in your body,
- you plan to have an examination of the thyroid,
- you are over 65 years old

Other warnings you should know about:

LIPIODOL ULTRA FLUID can cause:

- A decease in how well your kidneys work
- Existing kidney problems to get worse

It can also cause:

**Thyroid Dysfunction**

- Hyperthyroidism: an over-active thyroid gland
- Hypothyroidism: an under-active thyroid gland
- Thyroiditis: inflammation of the thyroid gland

**Allergic Disorders including Hypersensitivity, Anaphylactic or Anaphylactoid Reactions**

These are uncommon and can be mild to severe including death.

Most allergic disorders occur within 30 minutes. Reactions can also occur for up to several days. Your doctor should discuss symptoms of delayed allergic reactions with you.

**Cerebral Embolism and Blockages to Other Organs**: blockage of certain blood vessels in the brain.
Pulmonary Embolism: blockage of certain blood vessels in the lung. It usually occurs right away but can be delayed for hours to days.

Worsening Chronic Liver Disease: disease of the liver which lasts over a period of six months. It can cause heart problems, infection, irreversible liver damage and death.

Lymphoedema Aggravation: an accumulation of fluid in a body part. It is caused by a block of the lymph flow.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with LIPIODOL ULTRA FLUID:
- beta-blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers: these are drugs to treat eye disease, heart disease or high blood pressure,
- interleukin II drugs: These are drugs to treat cancer or to reinforce your immune system, i.e. your internal defence system,
- metformin: Drugs to treat diabetes. Your doctor should stop this drug 48 hours before the exam. It can be restarted 2 days after the exam,
- drugs that may cause damage to the kidney.

How to take LIPIODOL ULTRA FLUID:
Your doctor will prepare and inject this product before the exam. The route and method of injection depend on the reason the drug is being used.

Usual dose, route and method of administration
These depend on the reasons why LIPIODOL ULTRA FLUID is being used.

Your doctor will determine the dose to inject.

Overdose:

If you think you received too much LIPIODOL ULTRA FLUID, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

What are possible side effects from using LIPIODOL ULTRA FLUID?
These are not all possible side effects that you may feel when taking LIPIODOL ULTRA FLUID. If you experience any side effects not listed here, contact your healthcare professional. Please also see the Serious Warnings and Precautions box.

Side effects can include:
Shortness of breath and cough
Injection site pain and redness

LIPIODOL ULTRA FLUID can cause abnormal blood test results. Your doctor will decide when to preform blood tests and will interpret the results.

LIPIODOL ULTRA FLUID may interfere with thyroid diagnostic tests. It can cause changes to how the thyroid gland works. You may need to have a blood test to check the thyroid gland before using it. Thyroid blood test results can be affected for up to two years after taking LIPIODOL ULTRA FLUID.
### Serious side effects and what to do about them

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk to your healthcare professional</th>
<th>Stop taking drug and get immediate medical help</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td><strong>Thyroid Dysfunction:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypothyroidism:</strong> fatigue, increased sensitivity to cold, constipation, dry skin, weight gain, puffy face, hoarseness, muscle weakness, slowed heart rate, depression, impaired memory</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hyperthyroidism:</strong> difficulty concentrating, frequent bowel movements, goiter (visibly enlarged thyroid gland) or thyroid nodules, hair loss, hand tremor, heat intolerance, increased sweating, nervousness, weight loss, high blood pressure, bulging eyes</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Thyroiditis:</strong> feeling of fullness or pain in the neck, other symptoms similar to those of hypothyroidism or hyperthyroidism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea, vomiting, diarrhoea</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Fever, pain</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Granuloma:</strong> pain or tenderness in the lower abdominal area, vaginal infection</td>
<td></td>
<td><img src="https://example.com" alt="Granuloma" /></td>
</tr>
<tr>
<td><strong>Hepatic vein thrombosis:</strong> vomiting blood, black stools, enlarged spleen, swelling of lower limbs, abdominal pain (mainly in the upper right part of the abdomen), jaundice (yellowing of the skin and eyes)</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Allergic Disorder:</strong> rash or hives, flushing, pimples, itching and/or sudden swelling of the face, eyelids, lips, tongue or throat. Difficulty breathing or swallowing, wheezing, plugged nose, sneezing, coughing, dry throat, fever, chills, nausea, vomiting, diarrhoea, low blood pressure, and joint pain. Decreased urine output.</td>
<td></td>
<td><img src="https://example.com" alt="Allergic Disorder" /></td>
</tr>
<tr>
<td><strong>Cerebral Embolism and Blockages to Other Organs:</strong> severe headache, blurred vision, fainting, loss of consciousness, drowsiness, convulsion, confusion.</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Pulmonary Embolism:</strong> shortness of</td>
<td></td>
<td><img src="https://example.com" alt="Pulmonary Embolism" /></td>
</tr>
<tr>
<td>Symptom</td>
<td>Description</td>
<td>✓</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---</td>
</tr>
<tr>
<td><strong>Lymphoedema Aggravation:</strong></td>
<td>Swelling, heaviness, fullness and aching of body parts. Full or heavy sensation in the limb(s), tightness of the skin or tissue, decreased flexibility in the hand/wrist/foot/ankle, difficulty fitting into clothing in one specific area, or ring/wristwatch/bracelet tightness</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Worsening Chronic Liver Disease:</strong></td>
<td>Fever, chills, swollen or painful abdomen. Jaundice with yellow color to skin, eyes and dark urine. Increased blood pressure, headache and dizziness.</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Retinal Vein Thrombosis (Blood clot in the eye):</strong></td>
<td>Sudden loss of all or part of your vision or double vision.</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Salivary Duct Inflammation:</strong></td>
<td>Abnormal or foul tastes, decreased ability to open the mouth, dry mouth, fever, mouth or facial pain, especially when eating, swelling of the face</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Decreased kidney Function:</strong></td>
<td>Fatigue, lethargy, weakness, swelling, shortness of breath and confusion</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Worsening existing asthma:</strong></td>
<td>Cough, wheezing, shortness of breath, chest pain or pressure</td>
<td>✓</td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.
Reporting Side Effects
You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:
- Online at MedEffect;
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program
    Health Canada, Postal Locator 0701E
    Ottawa, ON
    K1A 0K9
    Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage: protect from light. Store at room temperature up to 30°C.

Keep out of reach and sight of children.

If you want more information about LIPIODOL ULTRA FLUID:
- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website; the importer’s website www.methapharm.com or by calling 1-800-287-7686 ext 7840.

This leaflet was prepared by Guerbet, BP 57400, 95943 ROISSY CDG Cedex, FRANCE.

Last Revised: July 12, 2017